MAA filed for Linhaliq in non-cystic fibrosis bronchiectasis

12 March 2018
aradigm-1-

A Marketing Authorization Application (MAA) has been filed with European Medicines Agency (EMA) for Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa).

US specialty drug firm Aradigm’s (Nasdaq: ARDM) Linhaliq, formerly known as Pulmaquin, is composed of a mixture of liposome encapsulated and unencapsulated ciprofloxacin. The product is being developed under a collaboration with Spanish drugmaker Grifols (GRLS: MC).

In January this year, Aradigm had a setback on the drug’s development, when it received a Complete Response Letter (CRL) from the US Food and Drug Administration, citing concerns including clinical data, human factors validation study and product quality, causing a near 40% slump in the firm’s share price.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical